Atorvastatin-induced prolonged cholestasis with bile duct damage
- PMID: 20155993
- DOI: 10.2165/11531660-000000000-00000
Atorvastatin-induced prolonged cholestasis with bile duct damage
Abstract
We report a case of acute-onset, long-lasting cholestasis induced by atorvastatin. This antihyperlipidaemic drug was taken for 40 days by a 72-year-old male as a treatment for his mixed dyslipidaemia. At that point, the patient presented with asthenia, nausea, painless icterus, acholic stools and hyperchromic urine with biochemical analyses showing a dramatic increase in bilirubin (total bilirubin 22 mg/dL; direct bilirubin 21 mg/dL) and alkaline phosphatase (up to 4-fold over the normal level) with less marked increases in transaminases. Liver histology showed a pattern of cholestasis with evident signs of cholangiolitis and damage of the interlobular bile ducts. Serum transaminase and bilirubin levels returned to normal within 5 months after atorvastatin withdrawal while alkaline phosphatase normalized after only 8 months. Scores on both the Maria and Victorino clinical scale for the diagnosis of drug-induced hepatitis and the Naranjo Adverse Drug Reaction Probability Scale indicated that atorvastatin was the probable cause of prolonged cholestasis in this patient. This is a rare case of cholestasis probably caused by atorvastatin and unusually characterized by bile duct damage.
Similar articles
-
Severe acute cholestatic hepatitis with prolonged cholestasis and bile-duct injury following atorvastatin therapy: a case report.Acta Gastroenterol Belg. 2008 Jul-Sep;71(3):318-20. Acta Gastroenterol Belg. 2008. PMID: 19198578
-
Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid.Hepatology. 2007 Sep;46(3):776-84. doi: 10.1002/hep.21741. Hepatology. 2007. PMID: 17668874
-
The biochemical and histopathological effects of ursodeoxycholic acid and metronidazole on total parenteral nutrition-associated hepatic dysfunction: an experimental study.Hepatogastroenterology. 2002 Mar-Apr;49(44):497-500. Hepatogastroenterology. 2002. PMID: 11995481
-
Prolonged cholestasis following endoscopic retrograde cholangiopancreatography, a rare complication of contrast agent induced liver injury: A case report and literature review.Medicine (Baltimore). 2020 Jan;99(3):e18855. doi: 10.1097/MD.0000000000018855. Medicine (Baltimore). 2020. PMID: 32011505 Free PMC article. Review.
-
Drug-induced bile duct injury.Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1498-1506. doi: 10.1016/j.bbadis.2017.08.033. Epub 2017 Sep 4. Biochim Biophys Acta Mol Basis Dis. 2018. PMID: 28882625 Review.
Cited by
-
miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity.EMBO Mol Med. 2012 Sep;4(9):882-95. doi: 10.1002/emmm.201201228. Epub 2012 Jul 5. EMBO Mol Med. 2012. PMID: 22767443 Free PMC article.
-
Effects of statins on cholestasis: good, bad or indifferent?J Gastroenterol Hepatol. 2011 Oct;26(10):1467-9. doi: 10.1111/j.1440-1746.2011.06836.x. J Gastroenterol Hepatol. 2011. PMID: 21950741 Free PMC article. No abstract available.
-
Virtual pathway explorer (viPEr) and pathway enrichment analysis tool (PEANuT): creating and analyzing focus networks to identify cross-talk between molecules and pathways.BMC Genomics. 2015 Oct 14;16:790. doi: 10.1186/s12864-015-2017-z. BMC Genomics. 2015. PMID: 26467653 Free PMC article.
-
Statin-induced Liver Injury Patterns: A Clinical Review.J Clin Transl Hepatol. 2022 Jun 28;10(3):543-552. doi: 10.14218/JCTH.2021.00271. Epub 2022 Jan 10. J Clin Transl Hepatol. 2022. PMID: 35836753 Free PMC article. Review.
-
Atorvastatin alters the expression of genes related to bile acid metabolism and circadian clock in livers of mice.PeerJ. 2017 May 18;5:e3348. doi: 10.7717/peerj.3348. eCollection 2017. PeerJ. 2017. PMID: 28533986 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources